Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Telomeres are the capping ends of chromosomes that protect the loss of genetic material and prevent chromosomal instability. In human tissue-specific stem/progenitor cells, telomere length (TL) is maintained by the telomerase complex, which consists of a reverse transcriptase catalytic subunit (TERT) and an RNA template (TERC). Very short telomeres and loss-of-function mutations in the TERT and TERC genes have been reported in acute myeloid leukemia, but the role of telomeres in acute promyelocytic leukemia (APL) has not been well established. We report the results for a large cohort of 187 PML/RARα-positive APL patients. No germline mutations in the TERT or TERC genes were identified. Codon 279 and 1062 TERT polymorphisms were present at a frequency similar to that in the general population. TL measured in blood or marrow mononuclear cells at diagnosis was significantly shorter in the APL patients than in healthy volunteers, and shorter telomeres at diagnosis were significantly associated with high-risk disease. For patients who achieved complete remission, the median increase in TL from diagnosis to remission (delta TL) was 2.0 kilobase (kb), and we found delta TL to be the most powerful predictor of overall survival when compared with well-established risk factors for poor outcomes in APL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hence, the opposition between telomere attrition and replicative immortality may be less prominent than has been widely thought.”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [127]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091 · cited 1×
“Telomerase activity is also often increased in neoplastic cells and is important for continuous cancer cell proliferation in human malignancies[3].”
BackgroundSwitching and Signaling at the Telomere
Blackburn, E. H. (2001) · Cell · doi:10.1016/s0092-8674(01)00492-5 · Cited by 2,107
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300874 · Cited by 1,611
All-trans-Retinoic Acid in Acute Promyelocytic Leukemia
Tallman, M. S., Andersen, J. W., Schiffer, C. A., Appelbaum, F. R., Feusner, J. H., Ogden, A., Shepherd, L., Willman, C., Bloomfield, C. D., Rowe, J. M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371501 · Cited by 1,073
Self-citationHeiss, N. S., Knight, S. W., Vulliamy, T. J., Klauck, S. M., Wiemann, S., Mason, P. J., Poustka, A., & Dokal, I. (1998) · Nature Genetics · doi:10.1038/ng0598-32 · Cited by 976
The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita
Vulliamy, T., Marrone, A., Goldman, F., Dearlove, A., Bessler, M., Mason, P. J., & Dokal, I. (2001) · Nature · doi:10.1038/35096585 · Cited by 960
Calado, R. T., & Young, N. S. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0903373 · Cited by 754
Mutations in TERT, the Gene for Telomerase Reverse Transcriptase, in Aplastic Anemia
Yamaguchi, H., Calado, R. T., Ly, H., Kajigaya, S., Baerlocher, G. M., Chanock, S. J., Lansdorp, P. M., & Young, N. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042980 · Cited by 723
Self-citationBurnett, A. K., Russell, N. H., Hills, R. K., Bowen, D., Kell, J., Knapper, S., Morgan, Y. G., Lok, J., Grech, A., Jones, G., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00193-x · Cited by 534
Cancer in dyskeratosis congenita
Alter, B. P., Giri, N., Savage, S. A., & Rosenberg, P. S. (2009) · Blood · doi:10.1182/blood-2008-12-192880 · Cited by 478
Cited by
Meta-hallmarks of aging and cancer
López-Otín, C., Pietrocola, F., Roiz-Valle, D., Galluzzi, L., & Kroemer, G. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2022.11.001 · Cited by 529
Differentiation syndrome with lower‐intensity treatments for acute myeloid leukemia
Fathi, A. T., Stein, E. M., Dinardo, C. D., Levis, M. J., Montesinos, P., & de Botton, S. (2021) · American Journal of Hematology · doi:10.1002/ajh.26142 · Cited by 48
Prognostic role of telomere length in malignancies: A meta-analysis and meta-regression
Adam, R., Díez-González, L., Ocaña, A., Šeruga, B., Amir, E., & Templeton, A. J. (2017) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2017.05.010 · Cited by 25
Telomere Length and Hematological Disorders: A Review
Nogueira, B. M. D., Machado, C. B., Montenegro, R. C., de Moraes, M. E. A., & Moreira-Nunes, C. A. (2020) · In Vivo · doi:10.21873/invivo.12142 · Cited by 25
Sharma, S., Tiwari, N., & Tanwar, S. S. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04069-z · Cited by 35
Biological and clinical implications of telomere dysfunction in myeloid malignancies
Kishtagari, A., & Watts, J. M. (2017) · Therapeutic Advances in Hematology · doi:10.1177/2040620717731549 · Cited by 15
Calvello, C., Rocca, B., Klersy, C., Zappatore, R., Giardini, I., Dambruoso, I., Pasi, F., Caresana, M., Zappasodi, P., Nano, R., et al. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1346252 · Cited by 11
“Very short telomeres and loss-of-function mutations in the TERT and TERC genes have been reported in AML [15,16].”
Genetic Variants of the TERT Gene and Telomere Length in Obstructive Sleep Apnea
Macek, P., Poręba, R., Gać, P., Bogunia‐Kubik, K., Dratwa, M., Wieckiewicz, M. A., Wojakowska, A., Michałek-Zrąbkowska, M., Mazur, G. J., & Martynowicz, H. (2022) · Biomedicines · doi:10.3390/biomedicines10112755 · Cited by 9
“It plays a vital role in maintaining telomere and chromosomal integrity and stability [13].”
BackgroundWarny, M., Helby, J., Sengeløv, H., Nordestgaard, B. G., Birgens, H., & Bojesen, S. E. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13196 · Cited by 11
A study of Telomerase Reverse Transcriptase rare variants in myeloid neoplasia
Gurnari, C., Wahida, A., Pagliuca, S., Durmaz, A., Zawit, M., Haferlach, T., Maciejewski, J. P., & Visconte, V. (2022) · Hematological Oncology · doi:10.1002/hon.2967 · Cited by 8
“Nevertheless, when focusing on specific subgroups (younger MDS undergoing HSCT, intermediate‐riskAML, acutepromyelocytic leukemia), thereby reducing the intra‐disease heterogeneity and possible confounding factors, studies have shown how TL may influence disease outcomes and survival.(15,16) To assess whether carriers…”
BackgroundThe Interplay of Aging and Cancer: Mechanisms, Implications, and Therapeutic Strategies
Wang, L., Luo, Y., Chen, X., Wang, Y., & Zhang, Y. (2025) · MedComm – Oncology · doi:10.1002/mog2.70041 · Cited by 10
Telomerase and Cancer: A Complex Relationship
Fossel, M., & Whittemore, K. (2021) · OBM Geriatrics · doi:10.21926/obm.geriatr.2101156 · Cited by 7
Gu, R., Cao, J., Wei, S., Gong, X., Wang, Y., Mi, Y., Zhang, J., Qiu, S., Rao, Q., Wang, M., et al. (2021) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13665 · Cited by 5
Aguilera-Diaz, A., Larráyoz, M. J., Palomino‐Echeverría, S., Vázquez, I., Ariceta, B., Mañú, A., Blasco‐Iturri, Z., Bernal, T., Salaverri, M. O., Rubio, M. T. O., et al. (2020) · Leukemia Research · doi:10.1016/j.leukres.2020.106386 · Cited by 4
Masuda, Y., Sadato, D., Toya, T., Hirama, C., Shimizu, H., Najima, Y., Harada, H., Harada, Y., & Doki, N. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06222-3 · Cited by 3
TERT rs2853669 as predictor for overall survival in patients with acute myeloid leukemia
Tripon, F., Bănescu, C. V., Trifa, A. P., Crauciuc, A., Moldovan, V. G., Bogliș, A., Benedek, I., Demian, S., Duicu, C., & Iancu, M. (2021) · Archives of Medical Science · doi:10.5114/aoms/100673 · Cited by 7
“important role in maintaining telomere stability and its length and therefore helps in preserving chromosomal stability [5].”
Backgroundde la Serna, J., Montesinos, P., & Sanz, M. Á. (2018) · Springer eBooks · doi:10.1007/978-3-319-64257-4_7
Characteristics of telomere length in patients with hematological diseases (literature review)
Kondratieva, Y. A., & Менделеева, Л. П. (2021) · Oncohematology · doi:10.17650/1818-8346-2021-16-1-23-30
“Таким образом, ДТ в какойто сте пени может рассматриваться в качестве предиктора течения и исхода заболевания при ОПЛ [30].”
Régulation épigénétique de la télomérase dans un modèle de leucémie aiguë promyélocytaire
Garsuault, D. (2019) · theses.fr (ABES) · doi:10.70675/b7ec8d0fz1565z4bfdz8f5ezad2c36aaffea
Metadata
- Authors
- Baljevic, M., Dumitriu, B., Lee, J.-W., Paietta, E. M., Wiernik, P. H., Racevskis, J., Chen, C., Stein, E. M., Gallagher, R. E., Rowe, J. M., Appelbaum, F. R., Powell, B. L., Larson, R. A., Coutré, S. E., Lancet, J., Litzow, M. R., Luger, S. M., Young, N. S., & Tallman, M. S.
- Affiliations
- National Institutes of Health (US)
- Dana-Farber Cancer Institute (US)
- Montefiore Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- Northwestern University (US)
- Fred Hutch Cancer Center (US)
- Atrium Health Wake Forest Baptist (US)
- University of Chicago (US)
- Moffitt Cancer Center (US)
- Mayo Clinic (US)
- University of Pennsylvania (US)
- ORCID
- Venue
- Acta Haematologica
- Publisher
- S. Karger AG
- Published
- 2016
- Volume
- 136
- Issue
- 4
- Pages
- 210-218
- ISSN
- 0001-5792 (ISSN-L)
- 1421-9662
- PMC
- PMC5198772
- OpenAlex
- W2519053332
- Cited by
- 20
- References
- 25
- Citations by year
- 2025: 3 · 2023: 1 · 2022: 2 · 2021: 6 · 2020: 2 · 2019: 1 · 2018: 2 · 2017: 3
- FWCI
- 1.61
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- karger.com/pages/terms-and-conditions (vor)
- karger.com/pages/terms-and-conditions (tdm)
- Locations
- Acta Haematologica (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Health and Human Services
- American College of Radiology Imaging Network
- National Institutes of Health
- National Cancer Institute (U10CA180816, U10CA180820, U10CA180791, UG1CA189859, U10CA180790, U10CA180819, U10CA180794, U10CA180821, P30CA008748, U24CA196172)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- telomere length, acute promyelocytic leukemia, PML-RARα, telomerase, overall survival, prognostic factors, complete remission, high-risk disease
- MeSH terms
- Adolescent, Adult, Aged, Codon, Female, Follow-Up Studies, Humans, Male, Middle Aged, Polymorphism, Genetic, RNA, Leukemia, Promyelocytic, Acute, Oncogene Proteins, Fusion, Survival Rate, Disease-Free Survival, Telomerase, Telomere Homeostasis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.